Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 07/16 09:59:48 pm
71.245 EUR   -0.92%
05:51pSANOFI : Disclosure of trading in own shares
GL
07/10SANOFI : denounces CADTH negative recommendation that could limit tr..
AQ
07/10SANOFI : France launches 100 million euros biotech fund
RE
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company usually posts poor financials for mid or long term investments.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is one of the best yield companies with high dividend expectations.
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Technically, the stock approaches a strong medium-term resistance at EUR 73.48.
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 74.36 EUR
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
SANOFI0.08%104 948
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193
AMGEN12.66%129 635
ABBOTT LABORATORIES10.50%110 556
GLAXOSMITHKLINE19.17%103 431
BAYER-8.75%101 760
ELI LILLY AND COMPANY6.22%97 374
NOVO NORDISK A/S-5.31%94 989
BRISTOL-MYERS SQUIBB COMPAN..-7.21%92 940
ASTRAZENECA7.44%92 021
CELGENE CORPORATION-17.89%62 110
ALLERGAN PLC8.30%60 065
More Results
Financials (€)
Sales 2018 35 013 M
EBIT 2018 8 316 M
Net income 2018 5 086 M
Debt 2018 15 904 M
Yield 2018 4,18%
P/E ratio 2018 17,28
P/E ratio 2019 16,14
EV / Sales 2018 3,02x
EV / Sales 2019 2,85x
Capitalization 89 713 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart SANOFI
Duration : Period : Day
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Duration : Period : Week
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders